Axon Enterprise (NASDAQ:AXON) Price Target Raised to $700.00

Axon Enterprise (NASDAQ:AXON) had its price target increased by The Goldman Sachs Group from $500.00 to $700.00 in a research report sent to investors on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on the stock. TD Cowen started coverage on shares of Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 target price for the company. Robert W. Baird lifted their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Needham & Company LLC increased their price target on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Northland Securities lifted their target price on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, JMP Securities boosted their price objective on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $524.85.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $639.97 on Monday. The firm’s fifty day simple moving average is $618.90 and its 200-day simple moving average is $477.78. Axon Enterprise has a fifty-two week low of $247.04 and a fifty-two week high of $698.67. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The stock has a market cap of $48.80 billion, a PE ratio of 165.37, a price-to-earnings-growth ratio of 6.09 and a beta of 1.04.

Insider Transactions at Axon Enterprise

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the transaction, the director now directly owns 6,929 shares in the company, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey C. Kunins sold 1,035 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $624.47, for a total transaction of $646,326.45. Following the transaction, the insider now directly owns 124,243 shares in the company, valued at approximately $77,586,026.21. The trade was a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,545 shares of company stock worth $30,721,337 in the last ninety days. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

Hedge funds have recently bought and sold shares of the stock. Public Sector Pension Investment Board grew its holdings in shares of Axon Enterprise by 79.5% in the second quarter. Public Sector Pension Investment Board now owns 2,604 shares of the biotechnology company’s stock valued at $766,000 after purchasing an additional 1,153 shares in the last quarter. MBB Public Markets I LLC purchased a new position in Axon Enterprise during the 2nd quarter valued at about $1,412,000. The Manufacturers Life Insurance Company grew its stake in Axon Enterprise by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 43,367 shares of the biotechnology company’s stock valued at $12,760,000 after purchasing an additional 535 shares during the last quarter. Creative Planning boosted its position in shares of Axon Enterprise by 9.6% in the 2nd quarter. Creative Planning now owns 16,463 shares of the biotechnology company’s stock worth $4,844,000 after purchasing an additional 1,441 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Axon Enterprise by 30.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 802 shares of the biotechnology company’s stock valued at $236,000 after acquiring an additional 188 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.